Malaria vaccine innovation

Stopping malaria to protect lives and promote growth.

Kinga Bora AG is developing a new generation of malaria vaccines designed to reduce severe disease burden where malaria becomes life-threatening, especially for children.

2nd-generation vaccine strategy Blood-stage targeting mRNA platform Global-health focus
Why this matters

Stopping malaria protects more than lives.

That malaria is not only fatal: it can remove years of education, income, and opportunity. A sick child affects the entire household, with downstream effects on human capital and long-term development.

2–10

School days missed per episode

3–5

Caregiver workdays lost

10–20%

Potential annual household income loss

3–4×

Higher risk of lasting cognitive impairment after severe malaria

Current challenge

A race against time — and climate change.

Limits of current tools

  • Prevention still relies heavily on bed nets and vector-control strategies.
  • Current pharmaceutical strategies are mainly focused on therapies.
  • First-generation vaccines are only partially effective.
  • Multiple doses are required, and protection can wane over time.
  • Broad protection for adults remains limited.

The threat is expanding geographically

Rising temperatures, flooding, and shifting mosquito habitats are factors that could broaden transmission zones beyond traditionally high-burden regions.

Sub-Saharan Africa Central America North of South America South-East Asia India Middle East Mediterranean risk zones Florida & beyond
Scientific approach

A second-generation strategy focused on the blood stage.

A vaccine concept designed to block parasite multiplication in the bloodstream, creating a longer time window to act than first-generation approaches that target the earliest stage of liver invasion.

1. Parasite enters host

Early-stage vaccines try to block the parasite before liver invasion.

2. Blood-stage multiplication

Kinga Bora focuses on preventing multiplication during the bloodstream phase.

3. Disease burden reduced

A longer intervention window may help reduce severe disease impact.

Why PfCyRPA

The target is presented as a potential weak point of the parasite.

Essential
Required for red-blood-cell invasion.
Conserved
Highly conserved across P. falciparum strains.
Functional
Antibodies can inhibit parasite growth.

Why mRNA

  • Strong antibody responses
  • Potentially faster and higher titers
  • Fewer injections than current vaccines
  • Rapid development and platform adaptability
  • Established scale-up and manufacturing experience
  • Clinically validated lipid nanoparticle delivery

Development history

  • Target characterization highlighted by Swiss TPH research.
  • Ongoing R&D advanced to animal studies.
  • Antisera and antibodies reported to inhibit parasite invasion into red blood cells.
  • High parasite-inhibitory antibody titers reported after 1–2 injections in the presentation.
Roadmap

From candidate selection to clinical proof of concept.

2026–2027

Manufacturing work, prototype development, rabbit immunogenicity testing, and early regulatory preparation.

2028

Preclinical package

GxP material manufacturing and GLP toxicology activities to support further advancement.

2029

Phase 1 first-in-human

Initial human studies planned in Australia, according to the roadmap in the presentation.

2030

Phase 1b / challenge work

Blood-stage challenge study planned in Australia.

2031–2032

Phase 2a / 2b expansion

African challenge study and pediatric Phase 2b progression form key value inflection points.

Access strategy

How to deliver solutions to people as fast as possible.

A late-stage strategy built around donor alignment, non-dilutive funding, and partnership with a multinational pharmaceutical company for approval, mass manufacturing, and distribution.

  • Strong donor interest in rapid access to efficacious vaccines
  • Potential for substantial non-dilutive funding in late-stage studies
  • Planned collaboration model with major pharma partners
Intellectual property

Protection of key inventions.

Enabling IP has been secured and additional patent filing activity is ongoing.

Known / published

  • Target: CyRPA
  • Protein and structure
  • Vaccine candidate data

Protected / being secured

  • Protein sequence / fragment
  • Codon-use adaptation
  • LNP packaging
  • Preclinical efficacy
  • Safety of LNP construct
People

The team and ecosystem.

Deep expertise spanning malaria, vaccines, global health, mRNA technologies, biotech company building, finance, and translational development.

CEO

Jörg Möhrle

Leadership in malaria-focused translational development.

CSO / Board Member  

Gerd Pluschke

Scientific leadership with malaria immunology and Swiss TPH research background.

Chairman

Roger Meier

Biotech company-building, governance, investor relations, and fundraising support.

Senior mRNA Advisor            

Justin Antony

mRNA platform, RNA technologies, and scale-up.

Board Member            

Marcel Tanner

Global-health, epidemiology, and malaria field expertise.

Operational support

Finance & Translation

CFO, accounting, controlling, administration, translation, and laboratory roles support execution.